Abstract
Pharmacoeconomics and pharmacoeconomic models are increasingly being used to guide health care decisions In designing and using these models, an appropriate balance must be struck between scientific rigour and model transparency. It is therefore important to consider carefully how the various model components, such as model perspective, internal and external validity, and choice of comparators and outcomes, should be integrated into the model. These factors are discussed in relation to the pharmacoeconomic evaluation of non-steroidal anti-inflammatory drugs.
Original language | English |
---|---|
Pages (from-to) | 29-32 |
Number of pages | 4 |
Journal | Rheumatology |
Volume | 39 |
Issue number | 2 |
Publication status | Published - Dec 2000 |
Keywords
- pharmacoeconomics
- NSAIDs
- health outcomes
- QUALITY-OF-LIFE
- RHEUMATOID-ARTHRITIS
- MEDICAL LITERATURE
- CLINICAL-PRACTICE
- USERS GUIDES
- OSTEOARTHRITIS
- ARTICLE